This inventor holds 1 USPTO granted patent. Top assignee: Other. Active years: 2022.
Company Filing History:
Years Active: 2022
Title: The Innovative Contributions of Jianyue Wu
Jianyue Wu is a notable inventor based in Shanghai, CN. He has made significant strides in the field of pharmaceuticals, particularly in the development of cancer treatment options. His work focuses on the creation of novel compounds that can potentially improve therapeutic outcomes for patients.
Latest Patents
Jianyue Wu holds a patent for a 5-fluorouracil derivative, which is a compound with promising applications in cancer treatment. The patent details a derivative characterized by a specific molecular structure, where Ra and Rb groups are alkoxy or fluorine-substituted alkoxy groups. These groups can be mono-, bis-, tri-, tetra-, or penta-substituted on a phenyl group. The linking groups in the compound are designed to enhance its efficacy in treating cancer, tumor diseases, and conditions caused by abnormal neovascularization in mammals. This innovative approach could lead to the development of new medicaments or compositions that utilize the 5-fluorouracil derivative.
Career Highlights
Throughout his career, Jianyue Wu has demonstrated a commitment to advancing medical science through his inventive work. His patent reflects a deep understanding of chemical structures and their potential applications in medicine. This achievement underscores his role as a key contributor to the field of pharmaceutical innovation.
Collaborations
Jianyue Wu has collaborated with notable colleagues, including Fanhong Wu and Xiaodong Yu. These partnerships have likely enriched his research and contributed to the successful development of his patented compounds.
Conclusion
In summary, Jianyue Wu is an accomplished inventor whose work in developing a 5-fluorouracil derivative showcases his innovative spirit and dedication to improving cancer treatment. His contributions to the field are significant and hold promise for future advancements in medical therapies.